# Amgen Inc. (AMGN) FY2024 YTD Q3 P&L / Income Statement

- Company: Amgen Inc. (AMGN)
- Period: 2024-01-01 to 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-10-31, accession number 0000318154-24-000044
- Page: https://plicit.ai/financials/amgn/fy2024-ytd-q3-income-statement
- Chart image: https://plicit.ai/charts/amgn-fy2024-ytd-q3-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2024-01-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 24,338,000,000 US dollars
- **Cost of sales**: 9,746,000,000 US dollars
- **Gross profit (calculated)**: 14,592,000,000 US dollars
- **Operating expenses (calculated)**: 9,645,000,000 US dollars
- **Operating income**: 4,947,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 1,120,000,000 US dollars
- **Income before income taxes**: 3,827,000,000 US dollars
- **Provision for income taxes**: 364,000,000 US dollars
- **Net income**: 3,463,000,000 US dollars
- **Aranesp - UNITED STATES**: 296,000,000 US dollars
- **Aranesp - Non-US**: 738,000,000 US dollars
- **BLINCYTO - UNITED STATES**: 555,000,000 US dollars
- **BLINCYTO - Non-US**: 280,000,000 US dollars
- **EVENITY - UNITED STATES**: 806,000,000 US dollars
- **EVENITY - Non-US**: 326,000,000 US dollars
- **ENBREL - UNITED STATES**: 2,280,000,000 US dollars
- **ENBREL - Non-US**: 21,000,000 US dollars
- **KRYSTEXXA - UNITED STATES**: 839,000,000 US dollars
- **KRYSTEXXA - Non-US**: 0 US dollars
- **Kyprolis - UNITED STATES**: 712,000,000 US dollars
- **Kyprolis - Non-US**: 419,000,000 US dollars
- **Nplate - UNITED STATES**: 749,000,000 US dollars
- **Nplate - Non-US**: 370,000,000 US dollars
- **Otezla - UNITED STATES**: 1,185,000,000 US dollars
- **Otezla - Non-US**: 317,000,000 US dollars
- **Other products - UNITED STATES**: 2,858,000,000 US dollars
- **Other products - Non-US**: 1,204,000,000 US dollars
- **Prolia - UNITED STATES**: 2,110,000,000 US dollars
- **Prolia - Non-US**: 1,099,000,000 US dollars
- **Repatha - UNITED STATES**: 824,000,000 US dollars
- **Repatha - Non-US**: 792,000,000 US dollars
- **TEPEZZA - UNITED STATES**: 1,379,000,000 US dollars
- **TEPEZZA - Non-US**: 12,000,000 US dollars
- **TEZSPIRE - UNITED STATES**: 676,000,000 US dollars
- **TEZSPIRE - Non-US**: 0 US dollars
- **Vectibix - UNITED STATES**: 385,000,000 US dollars
- **Vectibix - Non-US**: 414,000,000 US dollars
- **XGEVA - UNITED STATES**: 1,138,000,000 US dollars
- **XGEVA - Non-US**: 526,000,000 US dollars
- **Product sales - UNITED STATES**: 16,792,000,000 US dollars
- **Product sales - Non-US**: 6,518,000,000 US dollars
- **Research and development**: 4,240,000,000 US dollars
- **Selling, general and administrative**: 5,218,000,000 US dollars
- **Other**: 187,000,000 US dollars
- **Revenue before reconciliation (calculated)**: 46,620,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Components above reported revenue (calculated)**: negative 22,282,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.

## Chart details: Revenue by Product and Service (16 categories)

- Page: https://plicit.ai/financials/amgn/fy2024-ytd-q3-income-statement/revenue-by-product-and-service-16-categories
- Chart image: https://plicit.ai/charts/amgn-fy2024-ytd-q3-revenue-by-product-and-service-16-categories-sankey.png

Income statement for 2024-01-01 through 2024-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 24,338,000,000 US dollars
- **Cost of sales**: 9,746,000,000 US dollars
- **Gross profit (calculated)**: 14,592,000,000 US dollars
- **Operating expenses (calculated)**: 9,645,000,000 US dollars
- **Operating income**: 4,947,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 1,120,000,000 US dollars
- **Income before income taxes**: 3,827,000,000 US dollars
- **Provision for income taxes**: 364,000,000 US dollars
- **Net income**: 3,463,000,000 US dollars
- **Prolia**: 3,209,000,000 US dollars
- **ENBREL**: 2,301,000,000 US dollars
- **XGEVA**: 1,664,000,000 US dollars
- **Repatha**: 1,616,000,000 US dollars
- **Otezla**: 1,502,000,000 US dollars
- **TEPEZZA**: 1,391,000,000 US dollars
- **EVENITY**: 1,132,000,000 US dollars
- **Kyprolis**: 1,131,000,000 US dollars
- **Nplate**: 1,119,000,000 US dollars
- **Aranesp**: 1,034,000,000 US dollars
- **KRYSTEXXA**: 839,000,000 US dollars
- **BLINCYTO**: 835,000,000 US dollars
- **Vectibix**: 799,000,000 US dollars
- **TEZSPIRE**: 676,000,000 US dollars
- **Other products**: 4,062,000,000 US dollars
- **Other revenues**: 1,028,000,000 US dollars
- **Research and development**: 4,240,000,000 US dollars
- **Selling, general and administrative**: 5,218,000,000 US dollars
- **Other**: 187,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2 categories)

- Page: https://plicit.ai/financials/amgn/fy2024-ytd-q3-income-statement/revenue-by-product-and-service-2-categories
- Chart image: https://plicit.ai/charts/amgn-fy2024-ytd-q3-revenue-by-product-and-service-2-categories-sankey.png

Income statement for 2024-01-01 through 2024-09-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 24,338,000,000 US dollars
- **Cost of sales**: 9,746,000,000 US dollars
- **Gross profit (calculated)**: 14,592,000,000 US dollars
- **Operating expenses (calculated)**: 9,645,000,000 US dollars
- **Operating income**: 4,947,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 1,120,000,000 US dollars
- **Income before income taxes**: 3,827,000,000 US dollars
- **Provision for income taxes**: 364,000,000 US dollars
- **Net income**: 3,463,000,000 US dollars
- **Product sales**: 23,310,000,000 US dollars
- **Other revenues**: 1,028,000,000 US dollars
- **Research and development**: 4,240,000,000 US dollars
- **Selling, general and administrative**: 5,218,000,000 US dollars
- **Other**: 187,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.